This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Cardiometabolic Health Congress
NOVEMBER 16, 2023
2-5, 2023, to gain perspective on the latest advances in the management of glomerular disease. Kidney Week 2023 not only served as a platform for the latest news and updates in the field but also marked the final meeting of the year for practitioners in the specialty of nephrology.
American College of Cardiology
FEBRUARY 5, 2024
Hypertension represents a major modifiable risk factor for coronary artery disease (CAD), heart failure (HF), stroke, chronic kidney disease (CKD), and dementia.
75 
Journal of the American Heart Association
DECEMBER 1, 2023
Journal of the American Heart Association, Volume 12, Issue 23 , December 5, 2023.
Frontiers in Cardiovascular Medicine
MARCH 3, 2025
IntroductionSystemic inflammation is recognised as a critical driver of atherosclerotic cardiovascular disease (ASCVD), especially in patients with comorbid chronic kidney disease (CKD).
Stroke Journal
JANUARY 30, 2025
For the analysis, subjects were categorized as advanced chronic kidney disease (CKD, CrCl 15-30) and end stage renal disease (ESRD, CrCl<15).Results:Of From 2013 to 2023, Apixaban utilization increased the most in both groups from 1.1% Among those on apixaban 5mg dose, 24.5% in the CKD group and 0.6%
Cardiometabolic Health Congress
OCTOBER 26, 2023
A session at the 18 th Annual Cardiometabolic Health Congress (CMHC), explored the intersection of cardiometabolic conditions such as obesity and insulin resistance with liver disease, beginning with some important new updates on the preferred terms for these diseases. Available at: [link] (Accessed: October 24, 2023).
52 Hypertension Journal
SEPTEMBER 14, 2023
Hypertension, Volume 80, Issue 12 , Page 2533-2543, December 1, 2023. BACKGROUND:Hypertension frequently accompanies chronic kidney disease (CKD) as etiology and sequela.
Journal of the American Heart Association
DECEMBER 1, 2023
Journal of the American Heart Association, Volume 12, Issue 23 , December 5, 2023. BackgroundThe relationship between resting heart rate (RHR) and the risk of end‐stage renal disease (ESRD) among those without cardiovascular disease remains unclear. Of the participants, 32.6% had an RHR of ≥80 bpm.
75 
The American Journal of Cardiology
DECEMBER 13, 2023
Publication date: Available online 18 November 2023 Source: The American Journal of Cardiology Author(s): Anish K. Desai, Yaqub Betz, Antonio Abbate
Journal of Cardiovascular Pharmacology
SEPTEMBER 4, 2023
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Circulation
JANUARY 24, 2024
METHODS:The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing.
Journal of the American Heart Association
MARCH 25, 2025
BackgroundIn 2023, the American Heart Association defined the concept of cardiovascularkidneymetabolic (CKM) syndrome as a health disorder ascribed to connections among obesity, diabetes, chronic kidney disease, and cardiovascular disease. Journal of the American Heart Association, Ahead of Print.
Journal of the American Heart Association
NOVEMBER 28, 2023
Journal of the American Heart Association, Volume 12, Issue 23 , December 5, 2023. BackgroundCardiovascular calcification, characterized by deposition of calcium phosphate in the arterial wall and heart valves, is associated with cardiovascular morbidity and mortality and is commonly seen in aging, diabetes, and chronic kidney disease.
Journal of Cardiovascular Pharmacology
OCTOBER 9, 2024
This study compares outcomes in AF patients with GIB on AC alone to those on combination AP and AC therapy, as part of a larger prospective study from 2013 to 2023. This study compares outcomes in AF patients with GIB on AC alone to those on combination AP and AC therapy, as part of a larger prospective study from 2013 to 2023.
Cardiometabolic Health Congress
NOVEMBER 8, 2023
2023, the American Heart Association (AHA) issued a presidential advisory on the urgency of this systemic disorder involving heart disease, kidney disease, diabetes and obesity. Eckel, MD , chair of the Foundations of Cardiometabolic Health Certificate Course, has held appointments such as the Charles A.
Circulation
NOVEMBER 11, 2024
Evaluate the benefit in important cardiovascular outcomes and safety in elderly patients of a blood pressure control ≤ 130mmHg compared to standard of care.Methods:The research was performed in PubMed, EMBASE, Scielo, LILACS, and Cochrane Central Register of Controlled Trials (CENTRAL) from January 1st, 2013 to May 1st, 2023.
Circulation
NOVEMBER 11, 2024
Methods:STEMI patients who underwent coronary revascularization therapy and cardiac magnetic resonance (CMR) at about 4 days and 6 months between 2017 and 2023 were included. The patients were divided into groups (Group 1, FSF (-) during procedures with final TIMI-3; Group 2, FSF (+) with TIMI-3; Group 3, final angiogram was non-TIMI-3).
40 
The British Journal of Cardiology
MARCH 7, 2024
The Cardiorenal Forum’s recent 18 th Annual Scientific meeting looked at the latest updates in the failing heart and kidney.
40 
Stroke Journal
JANUARY 30, 2025
Propensity score-matched analysis (PSM) (1:1) was performed on age, gender, BMI, hypertension, diabetes mellitus, chronic kidney disease, hemoglobin level, LDL level, left ventricular ejection fraction and various drugs including beta blockers, ACEi and ARBi. Both groups were followed for 12 months.
Circulation
NOVEMBER 11, 2024
Data was obtained from the Hospital Corporation of America (HCA) enterprise-wide database from January 2020 to September 2023 using the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM).
Circulation: Genomic and Precision Medicine
DECEMBER 4, 2023
This systematic review and meta-analysis aimed to investigate the prevalence of FD in high-risk populations and newborns and evaluate the impact of differentGLAvariant classifications on the estimated prevalence of FD.METHODS:We searched the EMBASE and PubMed databases on February 21, 2023.
Cardiometabolic Health Congress
JULY 12, 2023
17-20, 2023, at the Laguna Cliffs Marriott Resort and Spa for the Women’s Cardiometabolic Health and Wellness Masterclass. Because our field lies at the intersection of so many vital clinical specialties, we have the unique opportunity to present on topics across the spectrum of medicine and reach our audience at cross-disciplinary events.”
40 
Dr. Smith's ECG Blog
SEPTEMBER 5, 2024
A VSR is more likely to occur in patients who are older, female, hypertensive, have chronic kidney disease, and have no prior history of smoking. It commonly occurs in the setting of a first myocardial infarction (MI) in the background of delayed or absent reperfusion therapy.
Stroke: Vascular and Interventional Neurology
NOVEMBER 9, 2023
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. IntroductionLateral medullary infarction (LMI) can present with dysphagia, dysphonia, dysarthria, vertigo, nausea, skew deviation, and ipsipulsion. Patients may also exhibit sensory loss and ipsilateral Horner’s syndrome.
40 
Stroke Journal
JANUARY 30, 2025
Propensity score-matched analysis (PSM) (1:1) was performed with matching for age, gender, race, BMI, hypertension, diabetes mellitus, chronic kidney disease, hemoglobin level, low-density lipid (LDL) level, left ventricular ejection fraction, and various drugs including ACEi, ARBi, ARNI, beta-blockers, and diuretics.
40 
Dr. Malcolm Kendrick
DECEMBER 8, 2023
8th December 2023 Nothing can simply be ‘good enough’. In addition, there are links to formal risk assessment in cardiovascular disease. With bonus hyperlinks to NICE’s guidelines on hypertension in chronic kidney disease and type I diabetes and type II diabetes and on and on.
Stroke: Vascular and Interventional Neurology
NOVEMBER 9, 2023
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. Risk factors such as smoking, chronic kidney disease, and aging can contribute to plaque formation.
40 
DAIC
DECEMBER 8, 2023
Getty Images milla1cf Fri, 12/08/2023 - 08:17 December 8, 2023 — The American College of Cardiology (ACC) and the American Heart Association (AHA), along with several other leading medical associations, have issued a new guideline for preventing and optimally managing atrial fibrillation (AFib).
DAIC
MARCH 26, 2025
2 Most are balancing multiple comorbidities, such as obesity, diabetes, hypertension and chronic kidney disease (CKD). 2023; Oct;29(10):1412-1451. Epub 2023 Sep 26. A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease (FIND-CKD).
Stroke Journal
JANUARY 30, 2025
Introduction:Chronic kidney disease (CKD) and ischemic stroke are both associated with significant global disease burdens and share common risk factors. Stroke, Volume 56, Issue Suppl_1 , Page ATP294-ATP294, February 1, 2025. Understanding the impact of CKD on stroke incidence is essential for improving patient outcomes.
Cardiometabolic Health Congress
JUNE 29, 2023
“We are pleased to announce our partnerships for the 2023 Women’s Cardiometabolic Health and Wellness Masterclass.
DAIC
JANUARY 19, 2024
milla1cf Fri, 01/19/2024 - 10:55 January 19, 2024 — Orchestra BioMed , a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the first patient was randomized in the BACKBEAT pivotal study in late December 2023. billion adults worldwide.
105 
DAIC
APRIL 9, 2024
UC Davis also hosted clinical trials for the procedure in 2023. “We Left untreated, tricuspid regurgitation can lead to atrial fibrillation , heart failure , kidney disease and even death. Food and Drug Administration (FDA) last week. Rogers , professor of cardiovascular medicine.
111 
Stroke Journal
OCTOBER 10, 2023
Stroke, Volume 54, Issue 12 , Page 3054-3063, December 1, 2023. BACKGROUND:Patients with end-stage kidney disease undergoing dialysis are at significant risk of stroke. Whether dialysis modality is associated with cerebrovascular disease is unclear.
CardiacWire
OCTOBER 6, 2024
Finerenone is already approved to reduce cardiovascular and kidney disease risks in patients with type 2 diabetes-associated CKD, but not for HF. Finerenone is a non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA), blocking the mineralocorticoid receptor and its blood pressure effects. in the future.
Hypertension Journal
OCTOBER 11, 2023
Hypertension, Volume 80, Issue 12 , Page 2591-2600, December 1, 2023. Urgent dialysis rates increased from 1.52% (95% CI, 1.12–2.06) 2.06) to 2.60% (2.17–3.1; Cochran-Armitage trend test;P=0.0071) in 48 235 patients, excluding maintenance dialysis patients.
40 Journal of Cardiovascular Pharmacology
DECEMBER 11, 2024
To compare the efficacy of SGLT2 inhibitors among non-older and older patients we have searched PubMed, Cochrane Central, and Embase until February 2023 for randomized controlled trials (RCTs) investigating SGLT2 inhibitors in older (age 65 years) patients with diabetes mellitus, chronic kidney disease, and chronic heart failure.
Stroke: Vascular and Interventional Neurology
NOVEMBER 9, 2023
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. 1.378]), and heart failure (1.282 [95%CI, 1.25‐1.315]).ConclusionPatient ConclusionPatient discharge disposition and comorbidities are driving factors in 90‐day readmissions following an ischemic stroke and differ from 30‐day readmissions.
40 
DAIC
JANUARY 23, 2024
As of June 2023, the U.S. colchicine which poses the greatest risk among patients 65 or older who may have declining liver or kidney function.38 Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study [published correction appears in J Am Coll Cardiol. Accessed November 8, 2023.
Stroke Journal
JANUARY 30, 2025
We aimed to examine the prevalence of VRFs among young patients with ICH and evaluate for racial and sex disparities in VRF burden.Methods:Data of patients hospitalized with stroke between January 2014 and December 2023 were collected by Get With the Guidelines-Stroke hospitals participating in the Florida Stroke Registry.
40 
Cardiometabolic Health Congress
JULY 25, 2023
Based on these results, updated diabetes guidelines recommend that in T2D patients with atherosclerotic cardiovascular disease, we should use GLP-1 RAs, and in T2D patients with heart failure or chronic kidney disease, we should use an SGLT-2 inhibitor after first-line therapy with lifestyle and metformin [25]. 18-21, 2023.
52 
Cardiometabolic Health Congress
DECEMBER 7, 2023
Published on November 30, 2023, in the Journal of the American College of Cardiology, these new guidelines are based on a comprehensive literature review from May 2022 to November 2022, and provide important recommendations to clinicians caring for patients with or at risk of developing cardiovascular disease (CVD). J Am Coll Cardiol.
Circulation
NOVEMBER 10, 2023
Circulation, Volume 148, Issue 24 , Page 1982-2004, December 12, 2023. Cardiovascular-kidney-metabolic (CKM) syndrome is a novel construct recently defined by the American Heart Association in response to the high prevalence of metabolic and kidney disease.
Frontiers in Cardiovascular Medicine
JANUARY 5, 2025
This study assessed the real-world use of vericiguat.Material and methodsThis cross-sectional, prospective and multicenter registry (VERISEC) included 776 patients from 43 centres in Spain between December 2022 and October 2023. Of these patients, 79.6% were male, with a mean age of 72.4 (SD:8.7)
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content